Werewolf Therapeutics Inc (HOWL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Werewolf Therapeutics Inc (HOWL) has a cash flow conversion efficiency ratio of -0.868x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.60 Million) by net assets ($12.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See HOWL net asset quality index to measure how much of total assets are equity-financed.
Werewolf Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Werewolf Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Werewolf Therapeutics Inc to evaluate the quality of earnings relative to operating cash generation.
Werewolf Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Werewolf Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lee Swee Kiat Group Bhd
KLSE:8079
|
-0.004x |
|
Minbos Resources Ltd
AU:MNB
|
-0.118x |
|
Algorae Pharmaceuticals Ltd
AU:1AI
|
-0.327x |
|
Herald Investment Trust
LSE:HRI
|
0.001x |
|
Energean Oil & Gas PLC
LSE:ENOG
|
0.428x |
|
Passat Société Anonyme
PA:PSAT
|
0.017x |
|
Xilam Animation
PA:XIL
|
0.207x |
|
GREAT PORTLAND ESTATES PLC
LSE:GPE
|
0.002x |
Annual Cash Flow Conversion Efficiency for Werewolf Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Werewolf Therapeutics Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Werewolf Therapeutics Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $24.80 Million | $-60.29 Million | -2.431x | -217.48% |
| 2024-12-31 | $73.39 Million | $-56.19 Million | -0.766x | -161.46% |
| 2023-12-31 | $111.37 Million | $-32.61 Million | -0.293x | +11.76% |
| 2022-12-31 | $122.34 Million | $-40.60 Million | -0.332x | -18.25% |
| 2021-12-31 | $152.79 Million | $-42.88 Million | -0.281x | -34.43% |
| 2020-12-31 | $89.22 Million | $-18.62 Million | -0.209x | +78.63% |
| 2019-12-31 | $9.77 Million | $-9.54 Million | -0.977x | -- |
About Werewolf Therapeutics Inc
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies throu… Read more